Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2021-11-01 Director's Dealing
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2021-11-01 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content specifically details the appointment of a new director to the Board of Directors, including biographical information and compensation details. This matches the description of Board/Management Information filings, which announce changes in the company's board or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, the correct classification is MANG (Board/Management Information). The document length and detail support a high confidence in this classification.
2021-10-28 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and that a press release announcing financial results for the quarter ended June 30, 2021, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The document length is 3787 characters, which is relatively short and consistent with a current report filing rather than a full financial report. According to the rules, such filings that announce or furnish a press release of quarterly financial results are classified as Earnings Release (ER).
2021-08-12 English
FORM 4
Director's Dealing
2021-07-02 English
SC 13D/A
Major Shareholding Notification
2021-06-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.